A Single Center Phase II Study of Ixazomib in Patients With Relapsed or Refractory Cutaneous or Peripheral T-Cell Lymphomas
American Journal of Hematology - United States
doi 10.1002/ajh.24895
Full Text
Open PDFAbstract
Available in full text
Categories
Date
September 25, 2017
Authors
Publisher
Wiley